Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | ACACB | O00763 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150869 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MLYCDMTNR1AMTNR1BACACB | |
| SCHEMBL8365133 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MLYCDMTNR1AMTNR1BACACB | |
| SCHEMBL17057670 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16351261 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL24600205 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16260515 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL16864727 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MTNR1AMTNR1BACACB | |
| SCHEMBL6728949 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL6728943 | 0.79 | MLYCD (0.42) | ALDH1A1MLYCDMEN1LMNAKMT2A | |
| SCHEMBL11273630 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11384064-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11192879-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200339539-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200325117-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020124397-A1 | C-TERMINAL SRC KINASE INHIBITORS | INVENTISBIO SHANGHAI LTD. (CN) | 2020-06-25 | — | — | WO | disclosed |
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2019147862-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-08-01 | — | — | US | disclosed |
| WO-2016046755-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-10683280-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20200325117-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20200339539-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-11192879-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-11384064-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
| US-20190233397-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | ALDH1A1 2077/4885MLYCD 3711/4885MTNR1A 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.